Polysialic acid is associated with better prognosis and IDH1-mutation in diffusely infiltrating astrocytomas
1 University of Tampere, School of Medicine, Biokatu 6, 33520 Tampere, Finland
2 Department of Pathology, Fimlab Laboratories, Biokatu 4, PL 2000, 33521 Tampere, Finland
3 Department of Pediatrics, Tampere University Hospital, Teiskontie 35, 33521 Tampere, Finland
4 Department of Biosciences, Division of Biochemistry and Biotechnology, University of Helsinki, P.O.B. 56, FI 00014 Helsinki, Finland
5 Department of Medical Biochemistry and Genetics, University of Turku, Kiinamyllynkatu 10, 20520 Turku, Finland
6 Department of Neurosurgery, Helsinki University Central Hospital, P.O. Box 266, FI-00029 Helsinki, Finland
7 Australian School of Advanced Medicine, 2 Technology Place, Macquarie University, Suite 201, Sydney NSW 2109, Australia
8 Unit of Neurosurgery, Tampere University Hospital, Teiskontie 35, 33521 Tampere, Finland
BMC Cancer 2014, 14:623 doi:10.1186/1471-2407-14-623Published: 28 August 2014
The aim of the study was to assess the localization of Polysialic acid (polySia) and Neural cell adhesion molecule (NCAM) in grade I–IV astrocytomas by confocal microscopy, and also to clarify and compare their relationship to conventional clinicopathological features in these tumors.
Study material was stained immunohistochemically for polySia, NCAM and IDH1-R132H point mutation. Confocal microscopy of polySia and NCAM staining was performed on tissue micro-array samples (TMA) of 242 diffusely infiltrating astrocytomas (grade II: 28; grade III: 33; grade IV: 181) and 82 pilocytic astrocytomas. The results were statistically correlated to clinicopathological factors and survival data.
PolySia was observed in 45 cases (19%) and NCAM positivity in 92 cases (38%). All 45 tumors with polySia positivity were also positive for NCAM whereas there were 47 tumors which contained positive staining for NCAM but not for polySia. The simultaneous expression was concomitant and colocalized suggesting polysialyated NCAM (polySia-NCAM). PolySia expression was significantly stronger in IDH1 mutated tumors than in IDH1 non-mutated (p = 0.001, chi-square test). There were no significant differences in polySia-NCAM between primary tumors or recurrences (p = n.s., chi-square test). PolySia positivity was associated with longer patient survival in relation to total tumor material (p = 0.020, log-rank test). Furthermore, when only glioblastomas were assessed, patients with positive polySia had significantly better prognosis (p = 0.006, log-rank test). In multivariate survival analysis, polySia was found to be an independent prognostic factor. PolySia was nearly absent in grade I pilocytic astrocytomas (1 immunopositive tumor of 82).
Expression of polySia is common in adult grade II–IV astrocytomas, whereas it is nearly absent in pediatric grade I pilocytic astrocytomas. PolySia positivity is associated with longer survival rates in patients with a grade II–IV astrocytomas and also grade IV glioblastomas assessed separately. The results of this study suggest that IDH1 mutation may be associated with polySia expression pathways in malignant gliomas.